NEOS Investment Management LLC Purchases 37,533 Shares of Genmab A/S (NASDAQ:GMAB)

NEOS Investment Management LLC boosted its position in Genmab A/S (NASDAQ:GMAB) by 91.2% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 78,683 shares of the company’s stock after purchasing an additional 37,533 shares during the period. NEOS Investment Management LLC’s holdings in Genmab A/S were worth $1,642,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC increased its position in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after purchasing an additional 939 shares during the last quarter. Lindbrook Capital LLC increased its holdings in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC increased its holdings in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after buying an additional 1,051 shares during the last quarter. Cromwell Holdings LLC raised its position in Genmab A/S by 656.8% in the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after acquiring an additional 2,496 shares during the period. Finally, R Squared Ltd purchased a new position in Genmab A/S in the fourth quarter valued at about $93,000. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Trading Down 1.2 %

Shares of NASDAQ:GMAB opened at $19.90 on Friday. The company has a 50 day moving average of $20.89 and a 200 day moving average of $21.88. The stock has a market cap of $13.17 billion, a P/E ratio of 11.44, a P/E/G ratio of 2.65 and a beta of 0.98. Genmab A/S has a 12 month low of $18.64 and a 12 month high of $30.50.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. On average, equities analysts forecast that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on GMAB shares. William Blair raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. BNP Paribas raised Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Thursday, January 23rd. Truist Financial lowered their price objective on Genmab A/S from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Tuesday, March 11th. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, December 20th. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.